| Literature DB >> 18308817 |
U E Lang1, M Willbring, R von Golitschek, A Schmeisser, K Matschke, S Malte Tugtekin.
Abstract
Clozapine is the drug of choice for treatment-resistant schizophrenia. Prompted by a patient who developed reversible clozapine-induced myocarditis after long-term treatment with clozapine for several years for chronic-resistant schizophrenia, we undertook a review of the relevant literature. Concerning the myocarditis, the patient recovered rapidly by withdrawal of clozapine and with supportive management. Psychiatric stabilisation of the patient was at least possible with a combination of quetiapine (600 mg) and amisulpride (800 mg). Well-designed studies with the aim to specifically investigate treatment options after clozapine are limited and clinical possibilities are discussed in this paper. Olanzapine and combinations using non-clozapine atypical neuroleptics have partly shown improvement, whereas evidence for successful augmentation with mood stabilisers, anticonvulsants or electroconvulsive therapy in treatment-resistant schizophrenia is limited.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18308817 DOI: 10.1177/0269881107082136
Source DB: PubMed Journal: J Psychopharmacol ISSN: 0269-8811 Impact factor: 4.153